MCID: CRR012
MIFTS: 20

Cirrhotic Cardiomyopathy

Categories: Liver diseases, Rare diseases, Cardiovascular diseases

Aliases & Classifications for Cirrhotic Cardiomyopathy

MalaCards integrated aliases for Cirrhotic Cardiomyopathy:

Name: Cirrhotic Cardiomyopathy 56

Characteristics:

Orphanet epidemiological data:

56
cirrhotic cardiomyopathy
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 56  
Rare hepatic diseases


External Ids:

Orphanet 56 ORPHA57777
ICD10 via Orphanet 34 I42.8

Summaries for Cirrhotic Cardiomyopathy

MalaCards based summary : Cirrhotic Cardiomyopathy is related to cardiomyopathy and liver disease. An important gene associated with Cirrhotic Cardiomyopathy is NPPA (Natriuretic Peptide A). The drugs Metoprolol and Dobutamine have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and brain.

Related Diseases for Cirrhotic Cardiomyopathy

Diseases related to Cirrhotic Cardiomyopathy via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 cardiomyopathy 10.6
2 liver disease 9.8
3 hepatorenal syndrome 9.8
4 hepatopulmonary syndrome 9.8
5 liver cirrhosis 9.7
6 portal hypertension 9.7
7 peritonitis 9.7

Graphical network of the top 20 diseases related to Cirrhotic Cardiomyopathy:



Diseases related to Cirrhotic Cardiomyopathy

Symptoms & Phenotypes for Cirrhotic Cardiomyopathy

Drugs & Therapeutics for Cirrhotic Cardiomyopathy

Drugs for Cirrhotic Cardiomyopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 21)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metoprolol Approved, Investigational Phase 3 37350-58-6, 51384-51-1 4171
2
Dobutamine Approved Phase 3 34368-04-2 36811
3 Adrenergic Agents Phase 3
4 Adrenergic Agonists Phase 3
5 Adrenergic Antagonists Phase 3
6 Adrenergic beta-1 Receptor Antagonists Phase 3
7 Adrenergic beta-Agonists Phase 3
8 Adrenergic beta-Antagonists Phase 3
9 Sympatholytics Phase 3
10 Neurotransmitter Agents Phase 3
11 Anti-Arrhythmia Agents Phase 3
12 Peripheral Nervous System Agents Phase 3
13 Protective Agents Phase 3
14 Antihypertensive Agents Phase 3
15 Autonomic Agents Phase 3
16
Carvedilol Approved, Investigational 72956-09-3 2585
17 Liver Extracts
18 Adrenergic alpha-1 Receptor Antagonists
19 Adrenergic alpha-Antagonists
20 Vasodilator Agents
21 Antioxidants

Interventional clinical trials:


id Name Status NCT ID Phase Drugs
1 DOCICAR: Cardiac Dysfunction in Cirrhosis Completed NCT00250315 Phase 3 Dobutamine
2 Metoprolol Succinate in Cardiac Remodeling Related to Cirrhosis Completed NCT01676285 Phase 3 Metoprolol succinate;placebo
3 Prospective Analysis Of Cardiac Function In Cirrhotic Patients By Echocardiography And Its Correlation With Events Unknown status NCT01433848
4 Heart Rate Variability Change After Liver Transplantation Completed NCT00778687
5 Therapeutic Approach to Diastolic Dysfunction in Chronic Liver Disease Patients and Its Impact on Morbidity and Mortality Completed NCT02294292 Carvedilol;Ivabradine
6 Subclinical Myocardial Dysfunction in Patients With Hepatic Cirrhosis Completed NCT01713478

Search NIH Clinical Center for Cirrhotic Cardiomyopathy

Genetic Tests for Cirrhotic Cardiomyopathy

Anatomical Context for Cirrhotic Cardiomyopathy

MalaCards organs/tissues related to Cirrhotic Cardiomyopathy:

39
Liver, Heart, Brain

Publications for Cirrhotic Cardiomyopathy

Articles related to Cirrhotic Cardiomyopathy:

(show top 50) (show all 71)
id Title Authors Year
1
Cirrhotic cardiomyopathy: is there any correlation between the stage of cardiac impairment and the severity of liver disease? ( 28245727 )
2017
2
Cirrhotic Cardiomyopathy: A New Clinical Phenotype. ( 28699978 )
2017
3
Cirrhotic cardiomyopathy: Implications for liver transplantation. ( 28407402 )
2017
4
The heart matters when the liver shatters! Cirrhotic cardiomyopathy: frequency, comparison, and correlation with severity of disease. ( 28053679 )
2016
5
Cirrhotic Cardiomyopathy: Another Case of a Successful Approach to Treatment of Hepatorenal Syndrome. ( 27843430 )
2016
6
Galactin-3 and brain natriuretic peptide versus conventional echocardiography in the early detection of cirrhotic cardiomyopathy. ( 27458853 )
2016
7
Minocycline attenuates cirrhotic cardiomyopathy and portal hypertension in a rat model: Possible involvement of nitric oxide pathway. ( 27917279 )
2016
8
Cirrhotic cardiomyopathy: Isn't stress evaluation always required for the diagnosis? ( 26839643 )
2016
9
Contribution of mammalian target of rapamycin in the pathophysiology of cirrhotic cardiomyopathy. ( 27217700 )
2016
10
Fragmented QRS is associated with cirrhotic cardiomyopathy in patients with decompensated cirrhosis. ( 27382936 )
2016
11
Prevalence of cirrhotic cardiomyopathy in patients with cirrhosis of liver. ( 27727569 )
2016
12
Impact and persistence of cirrhotic cardiomyopathy after liver transplantation. ( 27292629 )
2016
13
Assessment of cardiovascular physiology using dobutamine stress cardiovascular magnetic resonance reveals impaired contractile reserve in patients with cirrhotic cardiomyopathy. ( 26187817 )
2015
14
Hepatorenal syndrome with cirrhotic cardiomyopathy: case report and literature review. ( 25874140 )
2015
15
Cirrhotic cardiomyopathy: Implications for the perioperative management of liver transplant patients. ( 25848474 )
2015
16
Cirrhotic cardiomyopathy. ( 26556983 )
2015
17
Prevalence and impact on survival of hepatopulmonary syndrome and cirrhotic cardiomyopathy in a cohort of cirrhotic patients. ( 25974637 )
2015
18
Anti-Apoptosis Effects on Hearts of SHSST Cyclodextrin Complex in a Carbon Tetrachloride-induced Cirrhotic Cardiomyopathy Rat Model. ( 25687490 )
2015
19
Cirrhotic cardiomyopathy in the pre- and post-liver transplantation phase. ( 26074443 )
2015
20
Cirrhotic cardiomyopathy. ( 25870696 )
2014
21
SHSST cyclodextrin complex prevents the fibrosis effect on CCla88-induced cirrhotic cardiomyopathy in rats through TGF-I^ pathway inhibition effects. ( 24815066 )
2014
22
Recent Advances in Cirrhotic Cardiomyopathy. ( 25404411 )
2014
23
Diastolic dysfunction characterizes cirrhotic cardiomyopathy. ( 25634400 )
2014
24
Cardiomyocyte apoptosis contributes to pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated mice. ( 24712830 )
2014
25
Cirrhotic cardiomyopathy: review of pathophysiology and treatment. ( 25221635 )
2014
26
Opioid receptors blockade modulates apoptosis in a rat model of cirrhotic cardiomyopathy. ( 24971217 )
2014
27
Cirrhotic cardiomyopathy: A cardiologist's perspective. ( 25400434 )
2014
28
Pathophysiological and clinical approach to cirrhotic cardiomyopathy. ( 25267959 )
2014
29
New insights into cirrhotic cardiomyopathy. ( 23041091 )
2013
30
Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. ( 24217347 )
2013
31
Frequency and severity of cirrhotic cardiomyopathy and its possible relationship with bacterial endotoxemia. ( 23907333 )
2013
32
Does cirrhotic cardiomyopathy exist? 50 years of uncertainty. ( 23995321 )
2013
33
Cirrhotic cardiomyopathy and hepatopulmonary syndrome: prevalence and prognosis in a series of patients. ( 23615223 )
2013
34
Protective effects of erythropoietin on cirrhotic cardiomyopathy in rats. ( 22835858 )
2012
35
The heart: pathophysiology and clinical implications of cirrhotic cardiomyopathy. ( 23245476 )
2012
36
A perspective on cirrhotic cardiomyopathy. ( 21693251 )
2011
37
High brain-natriuretic peptide level predicts cirrhotic cardiomyopathy in liver transplant patients. ( 21276088 )
2011
38
Perioperative considerations in patients with cirrhotic cardiomyopathy. ( 20124994 )
2010
39
Cirrhotic cardiomyopathy. ( 20462649 )
2010
40
The role of lipophilic bile acids in the development of cirrhotic cardiomyopathy. ( 20414815 )
2010
41
Dobutamine stress echocardiography for evaluating cirrhotic cardiomyopathy in liver cirrhosis. ( 21415581 )
2010
42
Cirrhotic cardiomyopathy. ( 20688208 )
2010
43
Cirrhotic cardiomyopathy. ( 19669380 )
2009
44
Is the immediate reversal of diastolic dysfunction of cirrhotic cardiomyopathy after liver transplantation a sign of the metabolic etiology? ( 19877209 )
2009
45
Cirrhotic cardiomyopathy. ( 18293277 )
2008
46
Nuclear factor-kappaB inhibition improves myocardial contractility in rats with cirrhotic cardiomyopathy. ( 18346133 )
2008
47
Cirrhotic cardiomyopathy: Indian scenario. ( 17295773 )
2007
48
Cirrhotic cardiomyopathy: multiple reviews. ( 17717858 )
2007
49
Potential therapeutic targets in cirrhotic cardiomyopathy. ( 17346125 )
2007
50
Cirrhotic cardiomyopathy. ( 17383244 )
2007

Variations for Cirrhotic Cardiomyopathy

Expression for Cirrhotic Cardiomyopathy

Search GEO for disease gene expression data for Cirrhotic Cardiomyopathy.

Pathways for Cirrhotic Cardiomyopathy

GO Terms for Cirrhotic Cardiomyopathy

Sources for Cirrhotic Cardiomyopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....